A Phase 3 interventional study of icatibant in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 26 sites in 10 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-08.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 5th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 5th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →
icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2012.
This study's enrollment of 32 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 26 across the 10 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 10 have an industry lead sponsor. The 4 most frequent:
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
58 studies in Angioedemas, Hereditary by Takeda: 3 open now, 4 under way, none of them phase 3. Of 52 finished, 33 (63%) have results posted.
Among the 58 studies in Angioedemas, Hereditary by Takeda, this one is the 19th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2012, is one of 23 in phase 3, and was the 19th registered.
Takeda’s Angioedemas, Hereditary studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing icatibant in Angioedemas, Hereditary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 58 in Angioedemas, Hereditary:
This tab as a report to print or save as PDF → With an account.
HGT-FIR-086 is a multicenter, open-label, non-randomized, single-arm study to evaluate the Pharmacokinetics, tolerability,safety, and efficacy on reproductive hormones, of a single subcutaneous (SC) administration of icatibant in approximately 30 pediatric subjects with Hereditary Angioedema (HAE) during an initial acute attack.
Study HGT-FIR-086 will enroll 30 subjects from 2 to less than 18 years of age, divided into 2 groups: prepubertal and pubertal/postpubertal. At least 10 prepubertal children and at least 20 adolescents (including 10 treated during a HAE attack) must be enrolled in the study.
After a qualifying screening period, the PK, safety/tolerability, and efficacy of treatment with SC icatibant will be evaluated in at least 20 subjects (10 prepubertal and 10 pubertal/postpubertal subjects) who present with cutaneous, abdominal, or laryngeal symptoms of an acute attack of HAE. The PK and safety/tolerability of SC icatibant will be evaluated in at least 10 additional pubertal/postpubertal subjects who meet screening criteria and receive treatment with SC icatibant in the absence of a current acute HAE attack.
The planned duration of active participation for subjects who present with an initial attack of acute HAE will consist of treatment with a single subcutaneous injection of icatibant on Day 1 through follow up at day 90.
After having received initial treatment with icatibant, either during or in the absence of an attack, at least 10 pubertal/postpubertal subjects who subsequently experience an acute HAE attack may continue to receive treatment with icatibant as a single SC administration per attack for a total of 3 eligible icatibant-treated attacks.
The period of active participation in the study for prepubertal subjects will be approximately 90 days, while that for pubertal/postpubertal subjects could be a maximum of approximately 270 or 360 days (3 separate active periods of approximately 90 days for those treated with icatibant during an attack; 4 separate active periods for those treated without an attack), with each active period separated by periods of inactive participation of variable duration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Two through \<18 years of age at the time of first HAE attack.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
Drug: icatibant
Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
Also known as: Firazyr
Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant
Time to peak concentration (Tmax) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant
Maximum plasma concentration (Cmax) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant
Total plasma clearance (CL/F) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant
Area under the plasma concentration-time curve from time zero to 4 hours post-dose (AUC0-4) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, and 4 hours post-dose on Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant
Area under the plasma concentration-time curve from time zero to 6 hours post-dose (AUC0-t) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant
Volume of distribution (Vz/F) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Elimination Half-life (t1/2) of a Single Subcutaneous (SC) Dose of Icatibant
Elimination half-life (t1/2) of a single SC dose of icatibant was reported.
Time frame: Pre-dose; 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours post-dose on Day 1
Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs included pulse rate, blood pressure, respiration rate, and temperature. The number of participants who reported clinically significant changes in vital signs were reported.
Time frame: Pre-dose up to 97 days post-dose
Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs)
A standard 12-lead ECG was performed after 10 minutes at rest when the participant was seated or supine following treatment. The number of participants who reported clinically significant changes in ECGs were reported.
Time frame: 6 - 8 hours post-dose on Day 1
Number of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations
Clinical laboratory evaluations included clinical chemistry (including liver function tests), hematology, urinalysis. The number of participants who reported clinically significant changes in clinical laboratory evaluations were reported.
Time frame: Pre-dose up to 97 days post-dose
Number of Participants Who Reported Presence of Anti-icatibant Antibodies
The number of participants who reported anti-icatibant antibodies were reported.
Time frame: Pre-dose up to 97 days post-dose
Number of Participants With Adverse Events (AEs)
An AE was any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in a clinical study, whether or not considered investigational product related.
Time frame: From the start of study drug administration up to 97 days post-dose
Number of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 1
The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occured after initial icatibant administration was reported.
Time frame: 1 h post-dose on Day 1 up to 9 days post-dose
Number of Participants Who Reported Injection Site Reactions (ISR) for Icatibant Exposure Number 2 and 3
The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occurred after subsequent icatibant administration by study-site personnel (health care practitioner \[HCP\] administration) or by caregiver/self (caregiver administration) was reported. In the below table, E-2 refers to icatibant exposure 2 and E-3 refers to icatibant exposure 3.
Time frame: 1 h post-dose up to 9 days post-dose
Number of Participants With Clinically Significant Changes in Reproductive Hormones
Reproductive hormone levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone in females, and FSH, LH, and testosterone in males were measured. The number of participants with clinically significant changes in reproductive hormones was reported.
Time frame: Pre-dose up to 97 days post-dose
Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1
The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20 percent (%) improvement in the average post-treatment symptom score with no worsening of any single component score for the initial icatibant exposure. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of hereditary angioedema (HAE) using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received initial icatibant administration was reported.
Time frame: From start of study drug administration up to 8.5 hours post-dose
Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3
The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20% improvement in the composite (or average) post-treatment symptom score with no worsening of any single component score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
Time frame: From start of study drug administration up to 12 hours post-dose
Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1
The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received initial icatibant administration was reported.
Time frame: From start of study drug administration up to 52 hours post-dose
Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3
The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
Time frame: From start of study drug administration up to 28 hours post-dose
Time to Onset of Symptom Relief (TOSR) for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores
The TOSR was defined as the earliest time at which a 20% improvement was seen in the total post-treatment score. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. Face(F): 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); Legs(L): 0 (normal position/relaxed) - 2 (kicking/legs drawn up); Activity(A): 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); Cry(C): 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); Consolability(C): 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.
Time frame: From start of study drug administration up to 8.5 hours post-dose
Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1
Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received initial icatibant administration was reported.
Time frame: From start of study drug administration up to 8.5 hours post-dose
Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 2 and 3
Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
Time frame: From start of study drug administration up to 12 hours post-dose
Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1
Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received initial icatibant administration was reported.
Time frame: From start of study drug administration up to 52 hours post-dose
Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 2 and 3
Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
Time frame: From start of study drug administration up to 28 hours post-dose
Time to Minimum Symptom for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores
Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which the total post-treatment score improved to zero. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. (F) Face: 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); (L) Legs: 0 (normal position/relaxed) - 2 (kicking/legs drawn up); (A) Activity: 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); (C) Cry: 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); (C) Consolability: 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.
Time frame: From start of study drug administration up to 8.5 hours post-dose
Time to Use of Rescue Medication for the Treatment of Symptoms of the Hereditary Angioedema (HAE) Attack Following Study Drug Administration
Rescue medication was any medication used after the administration of icatibant which, in the opinion of the investigator, was immediately necessary to alleviate acute symptoms which are judged by the investigator as resultant from the current HAE attack. Time to first use of rescue medication prior to the onset of symptom relief was calculated from the time of study drug administration to the first use of rescue medication prior to the onset of symptom relief. This analysis was not performed since as per protocol, "This analysis will only be performed if there are at least 5 participants for a given attack who used rescue medication prior to attaining symptom relief".
Time frame: From the start of study drug administration up to 52 hours post-dose
Number of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 1
The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours postdose were reported.
Time frame: From 2 hours post-dose to 4 hours post-dose
Number of Participants With Worsened Intensity of Clinical Hereditary Angioedema (HAE) Symptoms Between 2 and 4 Hours After Treatment With Icatibant Exposure Number 2 and 3
The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours post-dose were reported.
Time frame: From 2 hours post-dose to 4 hours post-dose
The study was conducted at 27 study centers in the United States, Germany, Israel, Spain, Argentina, Australia, Austria, Canada, Colombia, Hungary, and Italy between 27 January 2012 (first participant first visit) and 12 March 2018 (last participant last visit).
| Milestone | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Started | 11 | 21 |
| Completed | 11 | 9 |
| Not completed | 0 | 12 |
| Withdrew: Withdrawal by subject | 0 | 9 |
| Withdrew: Lack of adherence and poor compliance | 0 | 3 |
| Milestone | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Started | 0 | 9 |
| Completed | 0 | 9 |
| Not completed | 0 | 0 |
| Milestone | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Started | 0 | 9 |
| Completed | 0 | 9 |
| Not completed | 0 | 0 |
Time to peak concentration (Tmax) of a single SC dose of icatibant was reported.
| Hour (h) | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Time to Peak Concentration (Tmax) of a Single Subcutaneous (SC) Dose of Icatibant | 0.42 ± 0.13 | 0.55 ± 0.19 | 0.57 ± 0.17 |
Maximum plasma concentration (Cmax) of a single SC dose of icatibant was reported.
| Nanogram per milliliter (ng/mL) | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) of a Single Subcutaneous (SC) Dose of Icatibant | 659 ± 158 | 805 ± 125 | 761 ± 133 |
Total plasma clearance (CL/F) of a single SC dose of icatibant was reported.
| Milliliters per minute (mL/min) | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Total Plasma Clearance (CL/F) of a Single Subcutaneous (SC) Dose of Icatibant | 10.8 ± 4.63 | 13.1 ± 3.42 | 19.3 ± 4.84 |
Area under the plasma concentration-time curve from time zero to 4 hours post-dose (AUC0-4) of a single SC dose of icatibant was reported.
| Hour*nanogram per milliliter (h*ng/mL) | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to 4 Hours Post-dose (AUC0-4) of a Single Subcutaneous (SC) Dose of Icatibant | 1241 ± 319 | 1448 ± 304 | 1335 ± 211 |
Area under the plasma concentration-time curve from time zero to 6 hours post-dose (AUC0-t) of a single SC dose of icatibant was reported.
| h*ng/mL | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours Post-dose (AUC0-t) of a Single Subcutaneous (SC) Dose of Icatibant | 1289 ± 325 | 1573 ± 372 | 1398 ± 225 |
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of a single SC dose of icatibant was reported.
| h*ng/mL | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of a Single Subcutaneous (SC) Dose of Icatibant | 1243 ± 244 | 1710 ± 569 | 1416 ± 229 |
Volume of distribution (Vz/F) of a single SC dose of icatibant was reported.
| Liters (L) | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Volume of Distribution (Vz/F) of a Single Subcutaneous (SC) Dose of Icatibant | 12.5 ± 5.28 | 23.5 ± 13.9 | 25.4 ± 8.87 |
Elimination half-life (t1/2) of a single SC dose of icatibant was reported.
| h | Prepubertal | Pubertal/Postpubertal: With Acute Attack | Pubertal/Postpubertal: Without Acute Attack |
|---|---|---|---|
| Elimination Half-life (t1/2) of a Single Subcutaneous (SC) Dose of Icatibant | 0.80 ± 0.04 | 1.34 ± 0.96 | 0.90 ± 0.10 |
Vital signs included pulse rate, blood pressure, respiration rate, and temperature. The number of participants who reported clinically significant changes in vital signs were reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 |
A standard 12-lead ECG was performed after 10 minutes at rest when the participant was seated or supine following treatment. The number of participants who reported clinically significant changes in ECGs were reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Electrocardiograms (ECGs) | 0 | 0 |
Clinical laboratory evaluations included clinical chemistry (including liver function tests), hematology, urinalysis. The number of participants who reported clinically significant changes in clinical laboratory evaluations were reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Clinical Laboratory Evaluations | 0 | 0 |
The number of participants who reported anti-icatibant antibodies were reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Number of Participants Who Reported Presence of Anti-icatibant Antibodies | 0 | 0 |
An AE was any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in a clinical study, whether or not considered investigational product related.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 2 | 11 |
The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occured after initial icatibant administration was reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Any Reaction | 9 | 20 |
| Any Severe Reaction | 0 | 2 |
The number of participants with injection site reactions (erythema, swelling, burning sensation, itching/pruritus, warm sensation, cutaneous pain, or other) that occurred after subsequent icatibant administration by study-site personnel (health care practitioner \[HCP\] administration) or by caregiver/self (caregiver administration) was reported. In the below table, E-2 refers to icatibant exposure 2 and E-3 refers to icatibant exposure 3.
| Participants | Pubertal/Postpubertal |
|---|---|
| E-2: HCP Administration: Any Reaction | 1 |
| E-2: HCP Administration: Any Severe Reaction | 0 |
| E-2: Caregiver Administration: Any Reaction | 8 |
| E-2: Caregiver Administration: Any Severe Reaction | 3 |
| E-3: HCP Administration: Any Reaction | 1 |
| E-3: HCP Administration: Any Severe Reaction | 0 |
| E-3: Caregiver Administration: Any Reaction | 7 |
| E-3: Caregiver Administration: Any Severe Reaction | 1 |
Reproductive hormone levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol, and progesterone in females, and FSH, LH, and testosterone in males were measured. The number of participants with clinically significant changes in reproductive hormones was reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Number of Participants With Clinically Significant Changes in Reproductive Hormones | 0 | 0 |
The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20 percent (%) improvement in the average post-treatment symptom score with no worsening of any single component score for the initial icatibant exposure. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of hereditary angioedema (HAE) using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received initial icatibant administration was reported.
| h | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Time to Onset of Symptom Relief (TOSR) for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1 | 1.0 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
The TOSR was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which there was at least a 20% improvement in the composite (or average) post-treatment symptom score with no worsening of any single component score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
| h | Pubertal/Postpubertal |
|---|---|
| Icatibant Exposure-2: HCP Administration | 4.0 (NA to NA) |
| Icatibant Exposure-2: Caregiver Administration | 1.0 (1.0 to 2.3) |
| Icatibant Exposure-3: HCP Administration | 1.0 (NA to NA) |
| Icatibant Exposure-3:Caregiver Administration | 1.1 (1.0 to 3.0) |
The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received initial icatibant administration was reported.
| h | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Time to Onset of Symptom Relief (TOSR) for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1 | 0.9 (0.8 to 1.0) | 1.0 (0.6 to 1.0) |
The TOSR was defined as the earliest time at which the post-treatment score improved by at least one level. Participants of 4 years age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). TOSR for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
| h | Pubertal/Postpubertal |
|---|---|
| Icatibant Exposure-2: HCP Administration | 3.0 (NA to NA) |
| Icatibant Exposure-2: Caregiver Administration | 1.0 (1.0 to 1.2) |
| Icatibant Exposure-3: HCP Administration | 1.0 (NA to NA) |
| Icatibant Exposure-3:Caregiver Administration | 1.1 (1.0 to 1.2) |
The TOSR was defined as the earliest time at which a 20% improvement was seen in the total post-treatment score. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. Face(F): 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); Legs(L): 0 (normal position/relaxed) - 2 (kicking/legs drawn up); Activity(A): 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); Cry(C): 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); Consolability(C): 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.
| h | Prepubertal |
|---|---|
| Time to Onset of Symptom Relief (TOSR) for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores | 1.0 (NA to NA) |
Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received initial icatibant administration was reported.
| h | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Time to Minimum Symptoms for Composite Investigator-Assessed Symptom Scores for Icatibant Exposure Number 1 | 1.9 (1.0 to 2.0) | 1.0 (1.0 to 2.0) |
Time to minimum symptom was defined as the duration of time in hours from study drug administration to the earliest time post-treatment at which all symptoms were either mild or absent for the investigator-reported symptom score. The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5-point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
| h | Pubertal/Postpubertal |
|---|---|
| Icatibant Exposure-2: Caregiver Administration | 1.2 (1.0 to 2.0) |
| Icatibant Exposure-3: Caregiver Administration | 2.2 (1.0 to NA) |
Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received initial icatibant administration was reported.
| h | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Time to Minimum Symptom for Faces Pain Scale-Revised (FPS-R) Scores for Icatibant Exposure Number 1 | 2.4 (1.9 to 5.3) | 3.8 (1.0 to 6.8) |
Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which post-treatment score improved to zero (or no pain). Participants of 4 years of age and older self-assessed their HAE-related pain using the FPS-R instrument. FPS-R is a self-reported measure used to assess the intensity of children's pain and it is scored using a 0 to 10 scale (0=no pain to 10=very much pain). Time to minimum symptom for participants who received subsequent icatibant administration by HCP administration or by caregiver/ self-administration was reported.
| h | Pubertal/Postpubertal |
|---|---|
| Icatibant Exposure-2: HCP Administration | 3.0 (NA to NA) |
| Icatibant Exposure-2: Caregiver Administration | 2.1 (1.0 to 4.0) |
| Icatibant Exposure-3: HCP Administration | 5.8 (NA to NA) |
| Icatibant Exposure-3:Caregiver Administration | 24.0 (3.8 to 24.2) |
Time to minimum symptoms was defined as the duration of time in hours from study drug administration to the earliest time at which the total post-treatment score improved to zero. Participants of 4 years age and younger underwent investigator assessment of HAE-related pain (cutaneous, abdominal, and laryngeal) using the FLACC comportmental pain scale. Each of the 5 categories was scored from 0 to 2. (F) Face: 0 (no particular expression/smile) - 2 (frequent to constant frown clenched jaw quivering chin); (L) Legs: 0 (normal position/relaxed) - 2 (kicking/legs drawn up); (A) Activity: 0 (lying quietly, normal position, moves easily) - 2 (arched rigid/jerking); (C) Cry: 0 (No cry \[awake/asleep\]) - 2 (crying steadily/screams/sobs or frequent complaints); (C) Consolability: 0 (content/relaxed) - 2 (difficult to console/comfort), resulting in a total score between 0 and 10.
| h | Prepubertal |
|---|---|
| Time to Minimum Symptom for Faces, Legs, Activity, Cry, and Consolability (FLACC) Scores | 1.0 (NA to NA) |
Rescue medication was any medication used after the administration of icatibant which, in the opinion of the investigator, was immediately necessary to alleviate acute symptoms which are judged by the investigator as resultant from the current HAE attack. Time to first use of rescue medication prior to the onset of symptom relief was calculated from the time of study drug administration to the first use of rescue medication prior to the onset of symptom relief. This analysis was not performed since as per protocol, "This analysis will only be performed if there are at least 5 participants for a given attack who used rescue medication prior to attaining symptom relief".
| h | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Time to Use of Rescue Medication for the Treatment of Symptoms of the Hereditary Angioedema (HAE) Attack Following Study Drug Administration | NA (NA to NA) | NA (NA to NA) |
The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours postdose were reported.
| Participants | Prepubertal | Pubertal/Postpubertal |
|---|---|---|
| Abdominal Tenderness | 0 | 1 |
| Nausea | 0 | 0 |
| Vomiting | 0 | 0 |
| Diarrhea | 0 | 0 |
| Skin Pain | 0 | 0 |
| Erythema | 0 | 0 |
| Skin Irritation | 0 | 0 |
| Skin Swelling | 0 | 0 |
The investigator used a symptom score to assess the severities of symptoms of acute cutaneous, abdominal, and laryngeal attacks of HAE using the following 5- point scale: 0=none (absence of symptoms), 1=mild (no to mild interference with daily activities), 2=moderate (moderate interference with daily activities), 3=severe (severe interference with daily activities) and 4=very severe (very severe interference with daily activities). The number of participants with a worsened severity of HAE symptoms at 4 hours post-dose from 2 hours post-dose were reported.
| Participants | Pubertal/Postpubertal |
|---|---|
| E-2: HCPA: Abdominal Tenderness | 0 |
| E-2:CA: Abdominal Tenderness | 0 |
| E-2: HCPA: Nausea | 0 |
| E-2: CA: Nausea | 0 |
| E-2:HCPA: Vomiting | 0 |
| E-2: CA: Vomiting | 0 |
| E-2: HCPA: Diarrhea | 0 |
| E-2: CA: Diarrhea | 0 |
| E-2: HCPA: Skin Pain | 0 |
| E-2: CA: Skin Pain | 0 |
| E-2: HCPA: Erythema | 0 |
| E-2: CA: Erythema | 0 |
| E-2: HCPA: Skin Irritation | 0 |
| E-2: CA: Skin Irritation | 0 |
| E-2: HCPA: Skin Swelling | 0 |
| E-2: CA: Skin Swelling | 0 |
| E-2: HCPA: Dysphagia | 0 |
| E-2: CA: Dysphagia | 0 |
| E-2: HCPA: Voice Change | 0 |
| E-2: CA: Voice Change | 0 |
| E-2: HCPA: Breathing Difficulties | 0 |
| E-2: CA: Breathing Difficulties | 0 |
| E-2: HCPA: Stridor | 0 |
| E-2: CA: Stridor | 0 |
| E-2: HCPA: Asphyxia | 0 |
| E-2:CA: Asphyxia | 0 |
| E-3: HCPA: Abdominal Tenderness | 0 |
| E-3: CA: Abdominal Tenderness | 1 |
| E-3: HCPA: Nausea | 0 |
| E-3: CA: Nausea | 0 |
| E-3: HCPA: Vomiting | 0 |
| E-3: CA: Vomiting | 0 |
| E-3: HCPA: Diarrhea | 0 |
| E-3: CA: Diarrhea | 1 |
| E-3: HCPA: Skin Pain | 0 |
| E-3: CA: Skin Pain | 0 |
| E-3: HCPA: Erythema | 0 |
| E-3: CA: Erythema | 0 |
| E-3: HCPA: Skin Irritation | 0 |
| E-3: CA: Skin Irritation | 0 |
| E-3: HCPA: Skin Swelling | 0 |
| E-3: CA: Skin Swelling | 0 |
| E-3: HCPA: Dysphagia | 0 |
| E-3: CA: Dysphagia | 0 |
| E-3: HCPA: Voice Change | 0 |
| E-3: CA: Voice Change | 0 |
| E-3: HCPA: Breathing Difficulties | 0 |
| E-3: CA: Breathing Difficulties | 0 |
| E-3: HCPA: Stridor | 0 |
| E-3: CA: Stridor | 0 |
| E-3: HCPA: Asphyxia | 0 |
| E-3: CA: Asphyxia | 0 |
Collected over From start of study drug administration up to 187 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Prepubertal | 0/11 (0%) | 0/11 (0%) | 4/11 (36.4%) |
| Pubertal/Post-pubertal | 0/21 (0%) | 0/21 (0%) | 8/21 (38.1%) |
| Overall | 0/32 (0%) | 0/32 (0%) | 12/32 (37.5%) |
| Event | Prepubertal | Pubertal/Post-pubertal | Overall |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/11 | 3/21 | 3/32 |
| ConjunctivitisEye disorders | 0/11 | 2/21 | 2/32 |
| Conjunctivitis allergicEye disorders | 0/11 | 2/21 | 2/32 |
| ToothacheGastrointestinal disorders | 0/11 | 2/21 | 2/32 |
| PyrexiaGeneral disorders | 0/11 | 2/21 | 2/32 |
| Upper respiratory tract infectionInfections and infestations | 1/11 | 2/21 | 3/32 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/11 | 2/21 | 2/32 |
| AnaemiaBlood and lymphatic system disorders | 1/11 | 0/21 | 1/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/11 | 0/21 | 1/32 |
| Epiphyseal fractureInjury, poisoning and procedural complications | 1/11 | 0/21 | 1/32 |
Safety population consisted of participants who were treated with icatibant at least once during the study.
| Age, Continuous(Years) | Prepubertal | Pubertal/Postpubertal | Total |
|---|---|---|---|
| Mean | 8.6 ± 2.97 | 14.3 ± 1.66 | 12.3 ± 3.48 |
| Sex: Female, Male(Participants) | Prepubertal | Pubertal/Postpubertal | Total |
|---|---|---|---|
| Female | 5 | 8 | 13 |
| Male | 6 | 13 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Prepubertal | Pubertal/Postpubertal | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 10 | 19 | 29 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Prepubertal | Pubertal/Postpubertal | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 11 | 20 | 31 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jan 2012 to primary completion in Mar 2018, 73 months.
Results were first posted in Mar 2019, 1 year after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 73 months is above that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Icatibant